Evaluation of a surgical treatment of denosumab-related osteonecrosis of the jaws

A Case of Osteonecrosis of the Jaw in a Patient with Crohn’s Disease Treated with Infliximab

“…MRONJ caused by intravenous and oral BPs has been extensively characterized over the last 13 years. To date, inhibitors of RANKL (denosumab) [ 8 , 14 ], of angiogenesis (bevacizumab and rituximab) [ 7 , 15 , 16 ], of tyrosine kinase receptors (sunitinib) [ 11 ], and of TNF (adalimumab) [ 10 ] have already been related to MRONJ in distinct case series, thus prompting the change in nomenclature from bisphosphonate-related osteonecrosis of the jaw (BRONJ) to MRONJ.…”

Prevalence, initiating factor, and treatment outcome of medication-related osteonecrosis of the jaw—a 4-year prospective study

“…Treatment choice for MRONJ is still controversial and recommendations from the American Association of Oral and Maxillofacial Surgeons (AAOMS) suggest antibacterial mouth rinses, symptomatic treatment with antibiotics in the early stages and, in more severe cases, superficial debridement for long term palliation of infection and pain 10 . More recent reports suggest a more radical treatment strategy with surgical removal of the necrotic bone and primary closure in combination with antibiotic treatment [15][16][17][18] .…”

Denosumab‐related osteonecrosis of the jaw following non‐surgical periodontal therapy: A case report

“…It is likely that inhibition of bone resorption by BPs was still present when our patient started denosumab and osteonecrosis developed, which makes it difficult to establish the role of each of these drugs in the development of the MRONJ, as has been suggested in previous series (Bagan et al., ). However, a time frame longer than 12 months between the discontinuation of BPs and the onset of denosumab treatment, as in the present case, is sufficient for the bone to recover its metabolic activity and consequently, to be able to attribute the appearance of MRONJ to denosumab (Pichardo & van Merkesteyn, ).…”